Latest Administration News

Page 50 of 164
Enlitic, Inc. reported a strong quarter with record cash receipts and contract wins, yet withdrew its revenue guidance due to delayed project completions. The company remains confident in reaching operational cash flow break-even by the end of Q4 FY25.
Victor Sage
Victor Sage
31 Oct 2025
Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug candidate NUZ-001 and strengthened its balance sheet with a $5.2 million capital raise. The company is now poised to enter the pivotal HEALEY ALS Platform Trial, marking a significant step forward in its neurodegenerative disease program.
Ada Torres
Ada Torres
31 Oct 2025
Cooper Metals is gearing up for drilling at its Mt Isa East copper-gold project while divesting a majority stake in its Gilberton Gold Project to Sybella Metals, maintaining a solid cash position to fund exploration.
Maxwell Dee
Maxwell Dee
31 Oct 2025
SRJ Technologies has made significant strides in its three-year growth plan, securing a $6 million joint venture with a Middle East National Oil Company and raising £1.4 million to fund its regional expansion.
Maxwell Dee
Maxwell Dee
31 Oct 2025
Alterity Therapeutics reports strengthened efficacy signals for ATH434 in Multiple System Atrophy and secures a robust cash position to fuel upcoming Phase 3 trials.
Ada Torres
Ada Torres
31 Oct 2025
Immuron Limited reports progress on its IMM-529 FDA application and a delay in Travelan® clinical trial results due to a U.S. government shutdown, with key data now expected in late November.
Ada Torres
Ada Torres
31 Oct 2025
Anagenics Limited reports a notable improvement in operating cash outflows for 1Q26, driven by cost efficiencies and strong brand performance, with Bouf Haircare on track to exceed $9 million in sales.
Victor Sage
Victor Sage
31 Oct 2025
Invion Limited has secured a pivotal FDA Orphan Drug Designation for its lead cancer drug INV043, bolstered its balance sheet with nearly $1.8 million in new funding, and progressed clinical trials targeting skin and anogenital cancers.
Ada Torres
Ada Torres
31 Oct 2025
Integral Diagnostics reports a robust FY25 with revenue climbing 33.7% to $628 million, driven by successful Capitol Health merger integration and strong growth in teleradiology. CEO Dr Ian Kadish announces retirement after eight transformative years.
Ada Torres
Ada Torres
31 Oct 2025
Bubs Australia reported a 30% increase in net revenue to $25.6 million for Q1 FY26, driven by robust US sales and a return to profitability with positive EBITDA. Despite inventory challenges in other regions, the company maintains a solid cash position and anticipates FDA approval by year-end.
Victor Sage
Victor Sage
31 Oct 2025
PainChek has secured FDA De Novo clearance for its Adult App, opening immediate access to a $175 million AUD US long-term care market and advancing its Infant App commercialization targeting a $15 billion AUD global opportunity.
Ada Torres
Ada Torres
31 Oct 2025
Mach7 Technologies reports a pivotal first quarter for FY26, marked by the initial go-live of a major U.S. Veterans Health Administration contract, leadership changes, and a strategic business reset.
Victor Sage
Victor Sage
31 Oct 2025